Biomarin Pharmaceutical (BMRN) Profit After Tax: 2009-2025
Historic Profit After Tax for Biomarin Pharmaceutical (BMRN) over the last 14 years, with Sep 2025 value amounting to -$30.7 million.
- Biomarin Pharmaceutical's Profit After Tax fell 128.98% to -$30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $520.4 million, marking a year-over-year increase of 61.47%. This contributed to the annual value of $426.9 million for FY2024, which is 154.62% up from last year.
- Latest data reveals that Biomarin Pharmaceutical reported Profit After Tax of -$30.7 million as of Q3 2025, which was down 112.78% from $240.5 million recorded in Q2 2025.
- Biomarin Pharmaceutical's Profit After Tax's 5-year high stood at $240.5 million during Q2 2025, with a 5-year trough of -$57.9 million in Q4 2021.
- Over the past 3 years, Biomarin Pharmaceutical's median Profit After Tax value was $88.7 million (recorded in 2024), while the average stood at $90.0 million.
- Per our database at Business Quant, Biomarin Pharmaceutical's Profit After Tax slumped by 440.02% in 2021 and then spiked by 8,282.73% in 2023.
- Biomarin Pharmaceutical's Profit After Tax (Quarterly) stood at -$57.9 million in 2021, then skyrocketed by 99.57% to -$249,000 in 2022, then spiked by 8,282.73% to $20.4 million in 2023, then surged by 513.22% to $124.9 million in 2024, then plummeted by 128.98% to -$30.7 million in 2025.
- Its Profit After Tax was -$30.7 million in Q3 2025, compared to $240.5 million in Q2 2025 and $185.7 million in Q1 2025.